SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

 

Bolt Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value

(Title of Class of Securities)

097702 104

(CUSIP Number)

Louis Rambo

Proskauer Rose LLP

1001 Pennsylvania Avenue, NW

Suite 600 South

Washington, DC 20004-2533

(202) 416-6878

Robert Hopfner

Pivotal bioVenture Partners Fund I U.G.P. Ltd

501 2nd Street, Suite 200

San Francisco, CA 94107

(415) 697-1002

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 12, 2024

(Date of Event Which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

Nan Fung Group Holdings Limited

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

AF

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

British Virgin Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

3,058,419

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

3,058,419

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,058,419

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

8.1%

14.   

Type of Reporting Person (See Instructions)

 

CO

 

2


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

NF Investment Holdings Limited

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

AF

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

British Virgin Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

3,058,419

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

3,058,419

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,058,419

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

8.1%

14.   

Type of Reporting Person (See Instructions)

 

CO

 

3


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

Pivotal bioVenture Partners Fund I, L.P.

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

WC

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

Cayman Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

1,891,467

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

1,891,467

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,891,467

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

5.0%

14.   

Type of Reporting Person (See Instructions)

 

PN

 

4


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

Pivotal bioVenture Partners Fund I G.P., L.P.

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

AF

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

Cayman Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

1,891,467

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

1,891,467

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,891,467

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

5.0%

14.   

Type of Reporting Person (See Instructions)

 

PN

 

5


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

Pivotal bioVenture Partners Fund I U.G.P. Ltd.

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

AF

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

Cayman Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

1,891,467

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

1,891,467

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,891,467

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

5.0%

14.   

Type of Reporting Person (See Instructions)

 

CO

 

6


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

Pivotal Partners Ltd

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

AF

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

Cayman Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

1,891,467

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

1,891,467

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,891,467

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

5.0%

14.   

Type of Reporting Person (See Instructions)

 

CO

 

7


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

Pivotal Life Sciences Holdings Limited

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

AF

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

Cayman Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

1,891,467

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

1,891,467

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,891,467

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

5.0%

14.   

Type of Reporting Person (See Instructions)

 

CO

 

8


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

Nan Fung Life Sciences Holdings Limited

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

AF

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

British Virgin Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

2,958,419

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

2,958,419

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

2,958,419

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

7.8%

14.   

Type of Reporting Person (See Instructions)

 

CO

 

9


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

Permwell Management Limited

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

WC

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

Cayman Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

100,000

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

100,000

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

100,000

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

0.3%

14.   

Type of Reporting Person (See Instructions)

 

CO

 

10


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

NFLS Beta Limited

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

WC

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

British Virgin Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

1,066,952

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

1,066,952

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,066,952

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

2.8%

14.   

Type of Reporting Person (See Instructions)

 

CO

 

11


CUSIP No. 097702 104

 

1.   

Names of Reporting Persons.

 

NFLS Platform Holdings Limited

2.   

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐  (b) ☒

 

3.   

SEC Use Only

 

4.   

Source of Funds (See Instructions)

 

WC

5.   

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

6.   

Citizenship or Place of Organization

 

Cayman Islands

Number of

Shares

Beneficially 

Owned by

Each

Reporting

Person

With

   7.   

Sole Voting Power

 

0

   8.   

Shared Voting Power

 

1,066,952

   9.   

Sole Dispositive Power

 

0

   10.   

Shared Dispositive Power

 

1,066,952

11.   

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,066,952

12.   

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

13.   

Percent of Class Represented by Amount in Row (11)

 

2.8%

14.   

Type of Reporting Person (See Instructions)

 

CO

 

12


Explanatory Note

This Schedule 13D/A is being filed as Amendment No. 2 (“Amendment No. 2”) to the Schedule 13D (as amended, the “Schedule 13D”) filed with the Securities and Exchange Commission on behalf of Nan Fung Group Holdings Limited, NF Investment Holdings Limited, Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund I G.P., L.P., Pivotal bioVenture Partners Fund I U.G.P., Ltd., Pivotal Partners Ltd, Pivotal Life Sciences Holdings Limited, Nan Fung Life Sciences Holdings Limited, Permwell Management Limited, NFLS Beta Limited and NFLS Platform Holdings Limited.

Item 2. Identity and Background

Item 2(a) and 2(f) are amended and restated as follows:

(a) This Schedule 13D is being filed by each of the following persons (each, a “Reporting Person”):

(i) Nan Fung Group Holdings Limited (“NFGHL”)

(ii) NF Investment Holdings Limited (“NFIHL”)

(iii) Nan Fung Life Sciences Holdings Limited (“Nan Fung Life Sciences”)

(iv) Pivotal bioVenture Partners Fund I, L.P. (“Pivotal”)

(v) Pivotal bioVenture Partners Fund I G.P., L.P. (“Pivotal GP”)

(vi) Pivotal bioVenture Partners Fund I U.G.P. Ltd. (the “Ultimate General Partner”)

(vii) Pivotal Partners Ltd (“Pivotal Partners”)

(viii) Pivotal Life Sciences Holdings Limited (“Pivotal Life Sciences,” and together with Pivotal, Pivotal GP, Ultimate General Partner, and Pivotal Partners, the “Pivotal Entities”)

(ix) Permwell Management Limited (“Permwell”)

(x) NFLS Beta Limited (“NFLS”)

(xi) NFLS Platform Holdings Limited (“NFLS Platform”)

Pivotal GP is the general partner of Pivotal, and Ultimate General Partner is the general partner of Pivotal GP. Ultimate General Partner is wholly-owned by Pivotal Partners. Pivotal Partners is wholly-owned by Pivotal Life Sciences. Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences, and Nan Fung Life Sciences is wholly-owned by NFIHL, which is wholly owned by NFGHL. Permwell is wholly-owned by NFIHL. NFLS is wholly-owned by NFLS Platform, which is wholly-owned by Nan Fung Life Sciences. The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal, Permwell, and NFLS. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Heqing Huang and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, is attached to Amendment No. 1 to the Schedule 13D as Exhibit 1.

(f) Pivotal is a Cayman Islands exempted limited partnership. Pivotal GP is a Cayman Islands exempted limited partnership. Ultimate General Partner is a Cayman Islands exempted company. Pivotal Partners is a Cayman Islands exempted company. Pivotal Life Sciences is a Cayman Islands exempted company. Nan Fung Life Sciences, NFIHL and NFGHL are incorporated in the British Virgin Islands. Permwell is incorporated in the Cayman Islands. NFLS is incorporated in the British Virgin Islands and NFLS Platform is incorporated in the Cayman Islands. Mr. Kam Chung Leung, Mr. Pui Kuen Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are citizens of the Hong Kong Special Administrative Region of the People’s Republic of China. Ms. Heqing Huang is a citizen of the People’s Republic of China. Mr. Frank Kai Shui Seto is a citizen of Canada. Mr. Vincent Sai Sing Cheung and Ms. Vanessa Tih Lin Cheung are citizens of the United Kingdom.

 

13


Item 5. Interest in Securities of the Issuer

Item 5 of the Schedule 13D is amended and restated as follows:

 

(a)

The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 37,965,870 outstanding shares of Common Stock, as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

In addition, Mr. Kam Chung Leung directly owns 173,698 shares of Common Stock.

 

(b)

The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

 

(c)

None of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

 

(d)

No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock subject to this Schedule 13D.

 

(e)

Not applicable.

 

14


SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 12, 2024
NAN FUNG GROUP HOLDINGS LIMITED
By:   /s/ Tang Chun Wai Nelson
Name:   Tang Chun Wai Nelson
Title:   Director
NF INVESTMENT HOLDINGS LIMITED
By:   /s/ Tang Chun Wai Nelson
Name:   Tang Chun Wai Nelson
Title:   Director
NAN FUNG LIFE SCIENCES HOLDINGS LIMITED
By:   /s/ Sun Xintong
Name:   Sun Xintong
Title:   Director

 

PIVOTAL BIOVENTURE PARTNERS FUND I, L.P.
By:   PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.
  Its General Partner,
  By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P., LTD.
  Its General Partner,
  By:   /s/ Robert Hopfner
  Name:   Robert Hopfner
  Title:   Authorized Signatory
PIVOTAL BIOVENTURE PARNTERS FUND I G.P., L.P.
By:   PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD
  Its General Partner,
  By:   /s/ Robert Hopfner
  Name:   Robert Hopfner
  Title:   Authorized Signatory

 

15


PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD
By:   /s/ Robert Hopfner
Name:   Robert Hopfner
Title:   Authorized Signatory
PIVOTAL PARTNERS LTD
By:   /s/ Sun Xintong
Name:   Sun Xintong
Title:   Director
PIVOTAL LIFE SCIENCES HOLDINGS LIMITED
By:   /s/ Sun Xintong
Name:   Sun Xintong
Title:   Director
PERMWELL MANAGEMENT LIMITED
By:   /s/ Tang Chun Wai Nelson
Name:   Tang Chun Wai Nelson
Title:   Director
NFLS BETA LIMITED
By:   /s/ Sun Xintong
Name:   Sun Xintong
Title:   Director
NFLS PLATFORM HOLDINGS LIMITED
By:   /s/ Sun Xintong
Name:   Sun Xintong
Title:   Director

 

16


Bolt Biotherapeutics (NASDAQ:BOLT)
過去 株価チャート
から 5 2024 まで 6 2024 Bolt Biotherapeuticsのチャートをもっと見るにはこちらをクリック
Bolt Biotherapeutics (NASDAQ:BOLT)
過去 株価チャート
から 6 2023 まで 6 2024 Bolt Biotherapeuticsのチャートをもっと見るにはこちらをクリック